FDG-PET/CT in re-staging of patients with lymphoma

European Journal of Nuclear Medicine - Tập 31 - Trang 325-329 - 2003
L. S. Freudenberg1, G. Antoch2, P. Schütt3, T. Beyer1, W. Jentzen1, S. P. Müller1, R. Görges1, M. R. Nowrousian3, A. Bockisch1, J. F. Debatin2
1Clinic and Policlinic for Nuclear Medicine, University of Essen, Essen, Germany
2Department of Radiology, University of Essen, Essen, Germany
3Department of Internal Medicine (Cancer Research), University of Essen, Essen, Germany

Tóm tắt

The aim of this study was to evaluate the clinical significance of combined fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in patients with lymphoma, and to compare the FDG-PET/CT staging results with those of FDG-PET and CT alone. Twenty-seven patients were studied. Each patient had clinical follow-up for >12 months and entered complete follow-up evaluation. Patient-based evaluation showed a sensitivity of 78% for CT alone, 86% for FDG-PET alone, 93% for CT and FDG-PET read side by side, and 93% for combined FDG-PET/CT imaging. Region-based evaluation showed a sensitivity for regional lymph node involvement of 61%, 78%, 91% and 96% respectively. FDG-PET/CT imaging is superior to CT alone (P=0.02) and has additional benefit over FDG-PET alone due to exact anatomical localisation. We conclude that FDG-PET/CT imaging is accurate in re-staging lymphoma and offers advantages over separate FDG-PET and CT imaging.

Tài liệu tham khảo

DeVita VT, Canellos GP. The lymphomas. Semin Hematol 1999; 36:84–94.

Jotti G, Bonadonna G. Prognostic factors in Hodgkin’s disease; implications for modern treatment. Anticancer Res 1988; 8:749–760.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.